Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation.
CAEBV is a high mortality and morbidity disease with life-threatening complications. Nevertheless, the treatment regimens for CAEBV have not yet been established. Although some reports have described CAEBV therapy involving treatments such as antiviral drugs, immunomodulatory agents, and immunochemotherapy, none of these treatments have been demonstrated to be effective. The only treatment reported to be effective is allogeneic SCT. However, the complications of SCT are severe, so treatment results have been poor. Recently, immunotherapy has been devised, but this is still in the developmental stage. In this report, two cases of CAEBV in which allogeneic SCT was performed soon after diagnosis are reported. In both cases, a high EBV genome titer in the peripheral blood was detected at onset. After SCT, the EBV genome titer decreased as CTL activity gradually increased. This fact suggested that not only high-dose chemotherapy as a preconditioning treatment of SCT but also increased CTL activity which could eliminate virus-infected cells might be effective, although additional cases should be studied in order to establish effective treatments.
Miyamura
Takako
T
Department of Pediatrics, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan. miyamu@md.okayama-u.ac.jp
Chayama
Kousuke
K
Wada
Tomoaki
T
Yamaguchi
Kazunari
K
Yamashita
Nobuko
N
Ishida
Toshiaki
T
Washio
Kana
K
Morishita
Naoto
N
Manki
Akira
A
Oda
Megumi
M
Morishima
Tsuneo
T
D000970:Antineoplastic Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D020031:Epstein-Barr Virus Infections / Q000097:blood* / Q000175:diagnosis*; D005260:Female; D016679:Genome, Viral; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D016219:Immunotherapy, Adoptive / Q000379:methods; D008297:Male; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D007155:Immunologic Factors